About Us
Elan is a neuroscience-focused biotechnology company headquartered in Dublin, Ireland. It was incorporated as a private limited company in December 1969 and became a public limited company in January 1984.
Elan's work includes research, development, and commercial activities for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease and autoimmune diseases, including multiple sclerosis.
JANSSEN Alzheimer Immunotherapy
Elan and Johnson & Johnson announced on September 17, 2009, that JANSSEN Alzheimer Immunotherapy, a Johnson & Johnson affiliate, had acquired substantially all of Elan’s assets related to the Alzheimer’s Immunotherapy Program (AIP) that Elan shared with Wyeth. Elan holds a 49.9% equity interest in JANSSEN Alzheimer Immunotherapy, and will be entitled to a 49.9% share of the profits and certain royalty payments upon the commercialization of AIP products.
JANSSEN Alzheimer Immunotherapy is continuing the AIP activities with Pfizer, which acquired Wyeth in 2009, to research, develop and commercialize selective products for the treatment and/or prevention of neurodegenerative conditions, including Alzheimer's disease. The program includes multiple compounds being evaluated for slowing the progression of Alzheimer's disease.
The lead compound (bapineuzumab), a potential first-in-class treatment that is being evaluated for slowing the progression of Alzheimer's disease, is administered intravenously once every three months and is in Phase 3 clinical trials. A subcutaneous formulation, administered once a week, is in Phase 2 trials. In addition, a vaccine for Alzheimer's disease (ACC-001) is also under development. (Learn more about AIP clinical trials).
Alkermes plc
On September 16, 2011, Alkermes plc and Elan Corporation, plc announced the completion of the merger between Alkermes, Inc. and Elan Drug Technologies (EDT), the drug formulation and manufacturing business unit of Elan, following the approval of the merger by Alkermes, Inc. shareholders on Sept. 8, 2011. The businesses were combined under a newly formed company, Alkermes plc, which is incorporated in Ireland and headquartered in Dublin. Alkermes plc is listed on the Nasdaq stock exchange under the ticker symbol "ALKS." Under the terms of the business combination agreement, Elan receives $500 million in cash and 31.9 million ordinary shares of Alkermes plc, representing approximately 25% of Alkermes plc.
Marketed Products
TYSABRI®
TYSABRI (natalizumab) is an approved therapy for relapsing forms of multiple sclerosis in the United States and relapsing-remitting multiple sclerosis in the European Union. TYSABRI is approved in the U.S. for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn's disease (CD) with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of TNF-alpha.
Important Product Safety Information TYSABRI MS
Important Product Safety Information TYSABRI Crohn's
Please see the Products section for prescribing information and Important Safety Information.
Key Facts
Locations
Dublin, Ireland (Headquarters)
South San Francisco, California
Employees: Approximately 400 worldwide
Company Registration
Elan Corporation, plc
Registered Office: Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland
Registered in Ireland
Registration Number 30356
Stock Exchange Listings
New York Stock Exchange (ELN)
Irish Stock Exchange
Investor Contacts
Chris Burns SVP, Global Investor Relations
Tel: 800-252-3526
Email: InvestorUS@elan.com
David Marshall PhD, VP, Global Investor Relations
Tel: 353-1-709-4444
Email: InvestorEurope@elan.com
Global Media Contacts
Niamh Lyons, VP, External Communications
+353-1-709-4176 or +353-87-774-5000